Dystrophic Epidermolysis Bullosa Market Insight, Epidemiology, And Market Forecast To 2036, VYJUVEK And ZEVASKYN Drive Regenerative Care

(MENAFN- GlobeNewsWire - Nasdaq) DEB offers opportunities for durable gene, gene-editing, cell and protein therapies; treatments for systemic fibrosis and cancer risk; easier home administration; improved diagnosis and access; and outcomes-based reimbursement.

Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Dystrophic Epidermolysis Bullosa - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

Dystrophic Epidermolysis Bullosa Market Forecast to Grow at a 7% CAGR Through 2036 as Gene and Cell Therapies Reshape Treatment

The "Dystrophic Epidermolysis Bullosa (DEB) - Market Insights, Epidemiology and Market Forecast - 2036" report provides a comprehensive assessment of the DEB treatment landscape, patient population, competitive environment, and commercial outlook across the United States, EU4 countries of Germany, France, Italy, and Spain, the United Kingdom, and Japan.

The dystrophic epidermolysis bullosa market is projected to expand at a compound annual growth rate of approximately 7% from 2026 to 2036. Growth is expected to be driven by the introduction of gene and cell therapies, continued pipeline development, increasing investment in rare disease research, and favorable regulatory pathways for innovative treatments.

Dystrophic Epidermolysis Bullosa Market Trends

DEB management is shifting from supportive care toward disease-modifying and regenerative strategies targeting pathogenic COL7A1 variants and type VII collagen restoration. Advanced wound care, infection prevention, pain management, nutritional support, and multidisciplinary intervention remain central to treatment. Patients with recessive dystrophic epidermolysis bullosa may also require surgical management of esophageal strictures, hand deformities, and persistent wounds.

Recent approvals have accelerated this transition. VYJUVEK, developed by Krystal Biotech, became the first topical gene therapy approved for DEB wounds, while ZEVASKYN from Abeona Therapeutics established a new treatment option as an autologous cell-based gene therapy for wounds in patients with recessive DEB. FILSUVEZ, marketed by Chiesi Farmaceutici, is approved for partial-thickness wounds associated with junctional and dystrophic epidermolysis bullosa.

Despite these advances, substantial unmet needs remain. Available treatments may require repeated administration, specialized procedures, or complex manufacturing and delivery. Most therapies focus primarily on wound healing and do not comprehensively address systemic fibrosis, chronic inflammation, disease-related deformities, or the elevated risk of aggressive cutaneous squamous cell carcinoma. The market therefore continues to require durable therapies capable of reducing treatment burden and delivering sustained clinical benefit.

DEB Epidemiology and Patient Population

Approximately 47,500 prevalent cases of epidermolysis bullosa were recorded across the seven major markets in 2025. Diagnosed prevalent DEB cases totaled approximately 14,300 and are forecast to increase through 2036. The United States accounted for the largest prevalent population, while Germany reported the highest number of cases among EU4 countries and the United Kingdom.

Children and young adults represented approximately 78% of epidermolysis bullosa cases in 2025. By subtype, epidermolysis bullosa simplex accounted for approximately 61% of cases, junctional epidermolysis bullosa represented 5%, and dystrophic epidermolysis bullosa accounted for approximately 34%.

Diagnosis is supported by clinical presentation, COL7A1 genetic testing, immunofluorescence mapping, and electron microscopy. Continued improvements in genetic testing, specialist referral, and disease awareness may increase diagnosis rates and expand the addressable DEB treatment market during the forecast period.

Approved DEB Therapies and Regulatory Developments

• VYJUVEK (beremagene geperpavec), Krystal Biotech: A topical, redosable gene therapy designed to deliver functional copies of COL7A1 directly to DEB wounds. In September 2025, the US Food and Drug Administration approved a label update extending eligibility to patients from birth and increasing flexibility in application and wound-dressing management. Japan granted marketing authorization in July 2025, allowing administration at home or in healthcare settings.
• ZEVASKYN (prademagene zamikeracel), Abeona Therapeutics: In April 2025, the FDA approved ZEVASKYN as an autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive DEB.
• FILSUVEZ (birch triterpenes), Chiesi Farmaceutici: The FDA approved FILSUVEZ in December 2023 for partial-thickness wounds in patients six months and older with junctional or dystrophic epidermolysis bullosa. The estimated total therapy cost is approximately USD 190,000, highlighting the importance of reimbursement and market-access planning.

Expanding Dystrophic Epidermolysis Bullosa Pipeline

The DEB pipeline includes gene replacement, gene editing, protein replacement, stem cell, anti-inflammatory, and combination gene-cell approaches. Developers are prioritizing greater durability, improved efficacy, broader wound coverage, and more convenient administration.

D-Fi, also known as dabocemagene autoficel or FCX-007, is an autologous gene therapy candidate developed through Castle Creek Biosciences' ex vivo platform. Its clinical development in recessive DEB has received support from the FDA's Office of Orphan Products Development.

RHEACELL is evaluating ABCB5-positive mesenchymal stem cells as a systemic therapeutic approach intended to reduce inflammation, support wound healing, and promote collagen VII deposition. Other next-generation programs include CRISPR-based gene editing, protein replacement, engineered skin grafts, and therapies targeting secondary inflammatory pathways.

Prominent companies in the dystrophic epidermolysis bullosa competitive landscape include Krystal Biotech, Chiesi Farmaceutici, Japan Tissue Engineering, Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, and Shionogi.

Key DEB Market Growth Drivers

• Advances in gene therapy, cell-based treatment, and regenerative medicine targeting the underlying molecular pathology of DEB.
• Expansion of the clinical pipeline across gene editing, protein replacement, stem cell, and anti-inflammatory therapeutic classes.
• Increasing biotechnology and pharmaceutical investment in rare dermatological diseases.
• Orphan drug designations, expedited review programs, and other regulatory incentives supporting clinical development.
• High unmet medical need and demand for treatments offering durable wound closure, reduced blistering, and lower treatment burden.
• Improved genetic diagnosis, specialist care pathways, and awareness of DEB across major healthcare markets.

Market Access, Pricing, and Reimbursement

The commercial success of DEB gene and cell therapies will depend on pricing, reimbursement, treatment-center capacity, manufacturing scalability, and evidence of durable clinical benefit. Payers are evaluating outcomes-based agreements, annuity arrangements, and risk-sharing models to manage the budget impact of high-cost advanced therapies.

Pricing assessments increasingly consider clinical durability, eligible patient population, degree of therapeutic innovation, caregiver burden, and potential reductions in wound-care utilization. Regional differences in reimbursement frameworks are expected to influence treatment uptake across the United States, Europe, the United Kingdom, and Japan.

Report Coverage and Strategic Insights

The report analyzes historical and forecast DEB epidemiology, treatment algorithms, therapy-specific market shares, drug uptake, peak patient share, pricing trends, and market growth from 2022 through 2036. It also evaluates approved products and Phase I-III pipeline therapies, including clinical data, mechanisms of action, patents, regulatory milestones, collaborations, and strategic partnerships.

Primary research incorporates perspectives from key opinion leaders and subject-matter experts across the seven major markets. Interviews with specialists affiliated with leading institutions, including the University of North Carolina at Chapel Hill, the Berlin Institute of Health at Charite, and the University of Nottingham, support analysis of treatment adoption, patient access, prescribing patterns, unmet needs, and clinical development priorities.

The assessment also includes SWOT and conjoint analyses covering efficacy, safety, administration frequency, route of administration, market-entry timing, probability of success, and addressable patient populations. These insights support competitive benchmarking, pipeline prioritization, market-access strategy, product positioning, and long-term commercial forecasting.

DEB Market Outlook Through 2036

The dystrophic epidermolysis bullosa treatment market is expected to maintain strong growth through 2036 as advanced therapies move into clinical practice and the pipeline continues to mature. The United States is projected to remain the largest DEB market, supported by regulatory innovation, specialist infrastructure, and earlier adoption of gene and cell therapies.

Although wound care and symptom management will remain essential, the future DEB treatment paradigm is expected to incorporate targeted genetic correction, regenerative medicine, systemic intervention, and combination therapy. Continued progress in durability, safety, accessibility, and reimbursement will be critical to translating scientific innovation into measurable improvements in patient outcomes and quality of life.

Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary of Dystrophic Epidermolysis Bullosa (DEB)
4. Key Events
4.1. Upcoming Key Catalysts
4.2. Key Conferences and Meetings
4.3. Key Transactions and Collaborations
4.4. News Flow
5. Epidemiology and Market Forecast Methodology
6. Dystrophic Epidermolysis Bullosa (DEB) Market Overview at a Glance
6.1. Market Share (%) Distribution by Therapies in 2025
6.2. Market Share (%) Distribution by Therapies in 2036
7. Disease Background and Overview of Dystrophic Epidermolysis Bullosa (DEB)
7.1. Introduction
7.2. Causes of Dystrophic Epidermolysis Bullosa (DEB)
7.3. Signs and Symptoms of Dystrophic Epidermolysis Bullosa (DEB)
7.4. Pathogenesis of Dystrophic Epidermolysis Bullosa (DEB)
7.5. Diagnosis of Dystrophic Epidermolysis Bullosa (DEB)
8. Treatment and Management of Dystrophic Epidermolysis Bullosa (DEB)
8.1. Management of Blisters
8.2. Skin and Wound Management
8.2.1. Management of Dystrophic Epidermolysis Bullosa (DEB)
9. Guidelines of Dystrophic Epidermolysis Bullosa (DEB)
9.1. Diagnostic Guidelines
9.1.1. Clinical Practice Guidelines for Dystrophic Epidermolysis Bullosa (DEB) Laboratory Diagnosis
9.1.2. Japanese Guidelines for Diagnosis and Treatment of Junctional and Dystrophic Epidermolysis Bullosa
10. Epidemiology and Patient Population of Dystrophic Epidermolysis Bullosa (DEB)
10.1. Key Findings
10.2. Assumption and Rationale
10.3. Total Diagnosed Prevalent Cases of Epidermolysis Bullosa
10.4. Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB)
10.5. The United States
10.5.1. Total Prevalent Cases of Epidermolysis Bullosa in the United States
10.5.2. Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in the United States
10.5.3. Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States
10.5.4. Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States
10.5.5. Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States
10.6. EU4 and the UK
10.6.1. Total Prevalent Cases of Epidermolysis Bullosa in EU4 and the UK
10.6.2. Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in EU4 and the UK
10.6.3. Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK
10.6.4. Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK
10.6.5. Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK
10.7. Japan
10.7.1. Total Prevalent Cases of Epidermolysis Bullosa in Japan
10.7.2. Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in Japan
10.7.3. Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan
10.7.4. Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan
10.7.5. Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan
11. Patient Journey
12. Marketed Drugs
12.1. Marketed Competitive Landscape of Dystrophic Epidermolysis Bullosa (DEB)
12.2. VYJUVEK (beremagene geperpavec): Krystal Biotech
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Developmental Activities
12.2.4. Summary of Pivotal Trials
12.2.4.1. Safety and Efficacy
12.2.5. Analyst's View
12.3. FILSUVEZ (oleogel-S10): Chiesi Farmaceutici
12.3.1. Product Description
12.3.2. Regulatory Milestones
12.3.3. Other Developmental Activities
12.3.4. Summary of Pivotal Trials
12.3.5. Safety and Efficacy
12.3.6. Analyst's View
List to be continued in the report..
13. Emerging Drugs
13.1. Emerging Competitive Landscape of Dystrophic Epidermolysis Bullosa (DEB)
13.2. D-Fi (dabocemagene autoficel): Castle Creek Biosciences
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Developmental Activities
13.2.3.1. Clinical Trial Information
13.2.4. Safety and Efficacy
13.2.5. Analyst's View
13.3. ABCB5+ mesenchymal stem cells (ABCB5+ MSCs): RHEACELL
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Developmental Activities
13.3.3.1. Clinical Trial Information
13.3.4. Safety and Efficacy
13.3.5. Analyst's View
13.4. Redasemtide: Shionogi
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Developmental Activities
13.4.3.1. Clinical Trial Information
13.4.4. Safety and Efficacy
13.4.5. Analyst's View
List to be continued in the report.
14. Dystrophic Epidermolysis Bullosa (DEB): 7MM Analysis
14.1. Key Findings
14.2. Market Outlook
14.3. Key Market Forecast Assumptions
14.4. Conjoint Analysis
14.5. Total Market Size of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM
14.6. United States Market Size
14.6.1. Total Market Size of Dystrophic Epidermolysis Bullosa (DEB) in the United States
14.6.2. Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging Therapies in the United States
14.7. EU4 and the UK Market Size
14.7.1. Total Market Size of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK
14.7.2. Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging Therapies in EU4 and the UK
14.8. Japan Market Size
14.8.1. Total Market Size of Dystrophic Epidermolysis Bullosa (DEB) in Japan
14.8.2. Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging Therapies in Japan
15. Unmet Needs of Dystrophic Epidermolysis Bullosa (DEB)
16. SWOT Analysis of Dystrophic Epidermolysis Bullosa (DEB)
17. KOL Views of Dystrophic Epidermolysis Bullosa (DEB)
18. Market Access and Reimbursement of Dystrophic Epidermolysis Bullosa (DEB)
18.1. United States
18.1.1. Centre for Medicare & Medicaid Services (CMS)
18.2. EU4 and the UK
18.2.1. Germany
18.2.2. France
18.2.3. Italy
18.2.4. Spain
18.2.5. United Kingdom
18.3. Japan
18.3.1. MHLW
18.4. Dystrophic Epidermolysis Bullosa (DEB): Market Access and Reimbursement
19. Appendix
19.1. Bibliography
19.2. Report Methodology
20. Analyst's Capabilities
21. Disclaimer
22. About the Publisher
List of Tables
Table 1: Summary of Dystrophic Epidermolysis Bullosa (DEB) Market and Epidemiology (2022-2036)
Table 2: DEB Subtypes and their Features
Table 3: Kindler Subtypes and their Features
Table 4: Recommendations for Laboratory Diagnosis of Dystrophic Epidermolysis Bullosa (DEB)
Table 5: Level of Evidence
Table 6: Grades of Recommendation Made by the Guideline Panel
Table 7: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in the 7MM
Table 8: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM
Table 9: Total Prevalent Cases of Epidermolysis Bullosa in the United States (2022-2036)
Table 10: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in the United States (2022-2036)
Table 11: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States
Table 12: Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States (2022-2036)
Table 13: Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States (2022-2036)
Table 14: Total Prevalent Cases of Epidermolysis Bullosa in EU4 and the UK (2022-2036)
Table 15: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in EU4 and the UK (2022-2036)
Table 16: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK (2022-2036)
Table 17: Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK (2022-2036)
Table 18: Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK (2022-2036)
Table 19: Total Prevalent Cases of Epidermolysis Bullosa in Japan (2022-2036)
Table 20: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in Japan (2022-2036)
Table 21: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan (2022-2036)
Table 22: Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan (2022-2036)
Table 23: Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan (2022-2036)
Table 24: Comparison of Marketed Drugs
Table 25: VYJUVEK (beremagene geperpavec), Clinical Trial Description, 2026
Table 26: Comparison of Emerging Drugs
Table 27: D-Fi (dabocemagene autoficel), Clinical Trial Description, 2026
Table 28: Allogenic ABCB5-positive Stem Cells, Clinical Trial Description, 2026
Table 29: Key Market Forecast Assumption of Dystrophic Epidermolysis Bullosa (DEB) in the US
Table 30: Key Market Forecast Assumption of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK
Table 31: Key Market Forecast Assumption of Dystrophic Epidermolysis Bullosa (DEB) in Japan
Table 32: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM, in USD million
Table 33: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in the US, in USD million (2022-2036)
Table 34: Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging in the US, in USD million (2022-2036)
Table 35: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK, in USD million (2022-2036)
Table 36: Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging Therapies in EU4 and the UK, in USD million (2022-2036)
Table 37: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in Japan, in USD million (2022-2036)
Table 38: Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging in Japan, in USD million (2022-2036)
List of Figures
Figure 1: Symptoms and Complications of Epidermolysis Bullosa Simplex
Figure 2: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in the 7MM
Figure 3: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM
Figure 4: Total Prevalent Cases of Epidermolysis Bullosa in the United States (2022-2036)
Figure 5: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in the United States (2022-2036)
Figure 6: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States
Figure 7: Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States (2022-2036)
Figure 8: Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in the United States (2022-2036)
Figure 9: Total Prevalent Cases of Epidermolysis Bullosa in EU4 and the UK (2022-2036)
Figure 10: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in EU4 and the UK (2022-2036)
Figure 11: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK (2022-2036)
Figure 12: Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK (2022-2036)
Figure 13: Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK (2022-2036)
Figure 14: Total Prevalent Cases of Epidermolysis Bullosa in Japan (2022-2036)
Figure 15: Total Diagnosed Prevalent Cases of Epidermolysis Bullosa in Japan (2022-2036)
Figure 16: Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan (2022-2036)
Figure 17: Gender-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan (2022-2036)
Figure 18: Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB) in Japan (2022-2036)
Figure 19: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM, in USD million (2022-2036)
Figure 20: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in the US, in USD million (2022-2036)
Figure 21: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in the US by Current and Emerging Therapies, in USD million (2022-2036)
Figure 22: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in EU4 and the UK, in USD million (2022-2036)
Figure 23: Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging Therapies in EU4 and the UK, in USD million (2022-2036)
Figure 24: Market Size of Dystrophic Epidermolysis Bullosa (DEB) in Japan, in USD million (2022-2036)
Figure 25: Market Size of Dystrophic Epidermolysis Bullosa (DEB) by Current and Emerging Therapies in Japan, in USD million (2022-2036)
Figure 26: Unmet Needs
Figure 27: Health Technology Assessment
Figure 28: Reimbursement Process in Germany
Figure 29: Reimbursement Process in France
Figure 30: Reimbursement Process in Italy
Figure 31: Reimbursement Process in Spain
Figure 32: Reimbursement Process in the United Kingdom
Figure 33: Reimbursement Process in Japan
A selection of companies mentioned in this report includes, but is not limited to:

• Krystal Biotech
• Chiesi Farmaceutici
• Japan Tissue Engineering
• Abeona Therapeutics
• Castle Creek Biosciences

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN10092026004107003653ID1111646581